Table 7 Sensitivity analysis III: Association between ranitidine use and cancer risk in which the person-time of patients diagnosed with cancer during the two-year lag-time period was excluded from the person-time summation.
From: Association between ranitidine use with potential NDMA impurities and risk of cancer in Korea
Exposure group | No. of patients | No. of events | 1000 person years | Incidence rate per 1000 person years (95% CI) | Crude HR | Adjusted HR† |
|---|---|---|---|---|---|---|
Overall cohort | ||||||
Ranitidine | 18 373 | 244 | 85.9 | 2.84 (2.50–3.22) | 1.01 (0.89–1.16) | 0.95 (0.83–1.09) |
Other H2RAs | 68 407 | 1731 | 528.6 | 3.27 (3.12–3.43) | Reference | Reference |
Propensity score matched cohort | ||||||
Ranitidine | 12 470 | 205 | 69.9 | 2.93 (2.55–3.36) | 1.00 (0.83–1.21) | 0.98 (0.81–1.19) |
Other H2RAs | 12 504 | 216 | 72.8 | 2.97 (2.58–3.39) | Reference | Reference |
